Opiant Pharmaceuticals Inc (OPNT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Opiant Pharmaceuticals Inc (OPNT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9841
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obese patients with binge eating disorder (BED), and for cocaine use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. The company is also developing opioid antagonists with a near term focus on cocaine use disorder, binge eating disorder (BED) and bulimia nervosa. Opiant is headquartered in Santa Monica, California, the US.

Opiant Pharmaceuticals Inc (OPNT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13
Opiant Pharma and Titan Pharma Enter into Agreement 14
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17
Lightlake Therapeutics To Enter Into Co-Development Agreement With King’s College London 18
Licensing Agreements 19
Consort Medical Enter into Development Agreement with Opiant Pharma 19
Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23
Equity Offering 24
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24
Opiant Pharma Raises USD12 Million in Public Offering of Shares 26
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28
Asset Transactions 29
Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29
Opiant Pharmaceuticals Inc – Key Competitors 30
Opiant Pharmaceuticals Inc – Key Employees 31
Opiant Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Nov 07, 2018: Opiant Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 33
Aug 09, 2018: Opiant Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 35
May 08, 2018: Opiant Pharmaceuticals Announces First Quarter 2018 Financial Results 37
Mar 07, 2018: Opiant Pharmaceuticals Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update 38
Dec 04, 2017: Opiant Pharmaceuticals Reports Fiscal First Quarter 2018 Financial Results 39
Oct 13, 2017: Opiant Pharmaceuticals Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 40
Jun 15, 2017: Opiant Pharmaceuticals Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update 42
Mar 16, 2017: Opiant Pharmaceuticals Reports Fiscal Second Quarter 2017 Financial Results and Provides Corporate Update 44
Corporate Communications 45
Oct 29, 2018: Opiant Pharmaceuticals names Craig Collard to Board of Directors 45
Jun 12, 2018: Opiant Pharmaceuticals Names Richard Daly As Board Director 46
Sep 05, 2017: Opiant Pharmaceuticals Announces Appointment of David O’Toole as Chief Financial Officer 47
Aug 28, 2017: Opiant Pharmaceuticals Announces Listing on the Nasdaq Capital Market 48
Feb 06, 2017: Opiant Pharmaceuticals Announces the Appointment of Dr. Phil Skolnick as Chief Scientific Officer 49
Product News 50
02/28/2017: Opiant Pharmaceuticals Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder 50
Clinical Trials 51
Feb 12, 2018: Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose 51
Dec 18, 2017: Opiant Pharma Announces Publication of New Pre-Clinical Data Supporting Potential of OPNT005 as a Heroin Vaccine 52
Jul 19, 2017: Opiant Pharmaceuticals Announces Phase I Data for OPNT002 in Development for the Treatment of Alcohol Use Disorder 53
Mar 20, 2017: Opiant Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Opiant Pharma Enters into Agreement with Biomedical Advanced Research and Development Authority 13
Opiant Pharma and Titan Pharma Enter into Agreement 14
Lightlake Therapeutics Enters into Agreement with University of Pennsylvania 15
Lightlake Therapeutics Enters Into Co-Development Agreement With National Institute On Drug Abuse 16
Lightlake Therapeutics Expands Co-Developmenet Agreement With National Institute On Drug Abuse 17
Lightlake Therapeutics To Enter Into Co-Development Agreement With King’s College London 18
Consort Medical Enter into Development Agreement with Opiant Pharma 19
Opiant Pharma Enters into Licensing Agreement with Aegis Therapeutics 20
Opiant Pharma Enters into Licensing Agreement with Walter Reed Army Institute of Research and National Institute on Drug Abuse 22
Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 23
Opiant Pharma Raises USD13.8 Million in Public Offering of Shares 24
Opiant Pharma Raises USD12 Million in Public Offering of Shares 26
Opiant Pharma Raises USD5.3 Million in Private Placement of Shares up on Exercise of Warrants 27
Opiant Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 28
Opiant Pharma Enters into Agreement with SWK for NARCAN Nasal Spray 29
Opiant Pharmaceuticals Inc, Key Competitors 30
Opiant Pharmaceuticals Inc, Key Employees 31
Opiant Pharmaceuticals Inc, Subsidiaries 32

List of Figures
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Opiant Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Opiant Pharmaceuticals Inc (OPNT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • A123 Systems LLC:企業の戦略的SWOT分析
    A123 Systems LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Itochu Enex Co Ltd (8133):企業の財務・戦略的SWOT分析
    Itochu Enex Co Ltd (8133) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • SpectraScience Inc (SCIE)-医療機器分野:企業M&A・提携分析
    Summary SpectraScience Inc (SpectraScience) is a medical device company, which undertakes the design, development, manufacture and marketing of light-based technology products. The company offers its proprietary WavSTAT Optical Biopsy System to diagnose tissue health optically by using light. This s …
  • Granules India Ltd (GRANULES):製薬・医療:M&Aディール及び事業提携情報
    Summary Granules India Ltd (Granules) is a pharmaceutical manufacturing company, which carries out the research, development and manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). The company manufactures Paracetomol, …
  • Mission Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Mission Therapeutics Ltd (Mission) is a drug discovery company that develops small molecule drugs targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company’s USP30 is the DUB that localizes to the outer mitochondrial membrane. Its USP7 is a DUB wit …
  • Massilly Holding S.A.
    Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report Summary Massilly Holding S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Econocom Group SA (ECONB):企業の財務・戦略的SWOT分析
    Econocom Group SA (ECONB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Linde plc (LIN):企業の財務・戦略的SWOT分析
    Linde plc (LIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Samchully Co Ltd (004690):企業の財務・戦略的SWOT分析
    Samchully Co Ltd (004690) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Suzlon Energy Ltd (SUZLON):企業の財務・戦略的SWOT分析
    Suzlon Energy Ltd (SUZLON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Duke Energy Carolinas LLC:発電所・企業SWOT分析
    Duke Energy Carolinas LLC – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emp …
  • PT. Indonesia Power:企業の発電所・SWOT分析2018
    PT. Indonesia Power - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Brown Brothers Harriman & Co:企業の戦略的SWOT分析
    Brown Brothers Harriman & Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Stefanini TechTeam, Inc.:企業の戦略的SWOT分析
    Stefanini TechTeam, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Shoprite Holdings Ltd:企業の戦略・SWOT・財務情報
    Shoprite Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Shoprite Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • TRACOE medical GmbH:企業の戦略的SWOT分析
    TRACOE medical GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • IOOF Holdings Ltd (IFL):企業の財務・戦略的SWOT分析
    IOOF Holdings Ltd (IFL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • ElectroCore Inc (ECOR):医療機器:M&Aディール及び事業提携情報
    Summary ElectroCore Inc (ElectroCore) is a bioelectronic medicine healthcare company. The company engaged in developing vagus nerve stimulation non-invasively (nVNS) therapy for neurology and rheumatology. It primarily focused on headache such as episodic cluster headache, migraine, and posttraumati …
  • Mylan NV (MYL)-製薬・医療分野:企業M&A・提携分析
    Summary Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, ca …
  • Exxon Mobil Corporation (XOM)-エネルギー分野:企業M&A・提携分析
    Summary Exxon Mobil Corporation (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. It is a major manufactu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆